HomeVertex

  • KALYDECO in Cystic Fibrosis receives positive CHMP opinion by EMA

    • October 21, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Positive results from new triple combinations in Cystic Fibrosis, displayed by Vertex

    • October 21, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Kalydeco (ivacaftor) Data Demonstrates Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of Cystic Fibrosis

    • June 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

    • April 30, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more